A new drug combination showed an advantage in three of a total of 10 patient groups with hepatitis C, particularly regarding virologic response, reviewers have found. The extent of added benefit remains unclear, however.
from Today's Healthcare News -- ScienceDaily http://ift.tt/1FB2Kvs
No comments:
Post a Comment